7190 results for "({!join from=dataset_studies to=id v=$q1}) OR ("transcriptome" OR "RNA-seq" OR "rna sequencing" OR "rna-sequencing")"

in 24.71 milliseconds.

• MiRNA_TrainTest

  Rounded Log2 CPM well-expressed miRNA levels in plasma; determined using the HTG EdgeSeq miRNA Whole Transcriptome Assay

  Dataset EGAD00010002754

• A single cell view on host immune transcriptional response to in vivo BCG-induced trained immunity

  Study EGAS00001006990

• SF10320

  SF10320 Unknown.

  Dataset EGAD00001006314

• GATCI RNAseq fastqs

  Raw RNA sequence data (fastq) for the GATCI project

  Dataset EGAD00001005810

• TEST3 Dataset

  TEST3 dataset containing 1 FASTQ file with mRNA reads.

  Dataset EGAD00001001920

• Transcriptome Sequencing Data of High Grade Serous Ovarian Cancer

  Study EGAS00001004714

• Identification_of_drug_resistance_genes_in_melanoma_by_mRNA_gene_expression

  We aim to sequence the mRNA transcriptome of 22 human melanoma cell lines in biological triplicate in order to define the gene expression profile of each cell line. The data will be correlated to the mutation status and the sensitivity to a panel of drugs in order to identify genes whose deregulation is associated to drug resistanceThis data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

  Study EGAS00001000815

• Transcriptome analysis of samples derived from GBM tumors, and relevant cell lines established and maintained at 5% or 20% oxygen.

  The goal of the study was to compare the transcriptome of patient-derived serum-free GBM cell lines to that of parental GBM tumors. For each patient, three samples were analyzed: GBM tumor, cell line growing at 5% oxygen, and cell line growing at 20% oxygen. Analysis demonstrated the enrichement in cell cycle and DNA repair gene expression in cell lines when compared to parental tumor sample. Moreover, cells cultured at 5% oxygen maintained hypoxia, carbon metabolism and tumor progression transcriptional pattern characteristic for GBM.

  Study EGAS00001006267

• A transcriptome atlas of human skeletal muscles

  We generated a large transcriptome atlas of human skeletal muscles by collecting biopsies from 6 different muscles to determine molecular signatures that may be distinct between leg muscles. The biopsies were collected from gracilis (GR), semitendinosus (ST), vastus lateralis (VL), vastus medialis (VM), rectus femoris (RF), and gastrocnemius lateralis (GL) muscles. We also investigated molecular differences within the muscle by including two biopsies from the middle and distal sides of the semitendinosus muscle (STM and STD, respectively). In total, 128 samples from 20 individuals (aged 25 ± 3.6 yr) were analyzed.

  Study EGAS00001005904

• Sebaceous carcinoma tumor/normal exome sequencing and transcriptome sequencing. Transcriptome sequencing of

  Sebaceous carcinomas (SeC) are cutaneous malignancies that, in rare cases, metastasize and prove fatal. Here we report whole exome sequencing on 32 SeC, revealing distinct mutational classes that explain both cancer ontogeny and clinical course. A UV-damage signature predominated 10/32 samples, while 9 were instead defined by microsatellite instability (MSI) mutations. UV-damage SeC exhibited poorly differentiated, infiltrative histopathologycompared to MSI signature SeC (p = 0.003), features previously associated with dissemination. Strikingly, UV-damage SeC transcriptomes and anatomic distributionclosely resembling those of cutaneous squamous cell carcinomas (SCC), implicating sun-exposed keratinocytes as a cell of origin. Like SCC, this UV-damage subclass harbors a high somatic mutation burden with >50 mutations/Mb, predicting immunotherapeutic response. In contrast, ocular SeC acquire far fewer mutations without a dominant signature, but show frequent truncating mutations in the ZNF750 epidermal differentiation regulator. Our data exemplify how different mutational processes convergently drive histopathologically related but clinically distinct cancers.

  Dataset EGAD00001004016

• TSO500 on RNA

  TruSight Oncology 500 RNA probes panel on case 521

  Dataset EGAD50000000271

• QuantSeq 3'-mRNAseq of pathogen-stimulated PBMCs

  5 donors, 4 stimuli, 2 time points

  Study EGAS50000000007

• The BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia

  Study EGAS00001006771

• RNAseq data

  RNAseq data for 10 patients: 10 tumors and 10 cell lines

  Dataset EGAD00001002691

• PCa RNASeq data

  RNASeq data from paired malignant/benign prostate tissues

  Dataset EGAD00001005931

• RNAseq

  RNAseq of pancreatic cancer organoids.

  Dataset EGAD00001010834

• LCNEC study - RNAseq data set

  RNAseq Data set

  Dataset EGAD00001003801

• Spatial Transcriptomic BC ILC

  Fastq files from 4 Visium spatial transcriptomic ILC sections

  Dataset EGAD50000002494

• Integrated clinical, whole genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer

  We report the first combined analysis of whole genome sequence, detailed clinical history, and transcriptome sequence of multiple prostate cancer metastases in a single patient (A21). Whole genome and transcriptome sequence was obtained from 9 anatomically separate metastases, and targeted DNA sequencing was performed in cancerous and noncancerous foci within the primary tumor specimen removed 5 years prior to death. Transcriptome analysis revealed increased expression of AR-regulated genes in liver metastases that harbored an AR p.L702H mutation, suggesting a dominant effect by the mutation despite being present in only 1 of an estimated 16 copies per cell. The metastases harbored several alterations to the PI3K/AKT pathway, including a clonal truncal mutation in PIK3CG and present in all metastatic sites studied. The list of truncal genomic alterations shared by all metastases included homozygous deletion of TP53, hemizygous deletion of RB1 and CHD1, and amplification of FGFR1. If the patient were treated today given this knowledge, use of second-generation androgen-directed therapies, cessation of glucocorticoid administration, and therapeutic inhibition of the PI3K/AKT pathway or FGFR1 receptor could provide personalized benefit. Three previously unreported truncal clonal missense mutations (ABCC4 p.R891L, ALDH9A1 p.W89R, and ASNA1 p.P75R) were expressed at the RNA level and assessed as druggable. The truncal status of mutations is critical for actionability, and can only be determined through analysis of multiple sites of metastasis. Our findings suggest that a large set of deeply analyzed cases could serve as powerful guide to more effective prostate cancer basic science and personalized cancer medicine clinical trials.

  Study EGAS00001001659

• Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma

  Dataset EGAD00001003324

• Transcriptome sequencing of Gingivo-buccal Cancer : ICGC-India Project_2020

  Dataset EGAD00001006003

• Dataset for study EGAS00001004946 (Endothelium-derived stromal cells contribute to bone marrow niche formation)

  Dataset EGAD00001006914

• RNAseq for 190 AML patients

  This dataset contains 190 fastq files sequenced with Illumina HiSeq500.

  Dataset EGAD50000000490

• Single nuclei sequencing (snRNA-seq) of patient tumours

  snRNA-seq was performed on patient samples

  Study EGAS50000000617

• ORIENT study

  scRNAseq dataset containing 5 healthy donors and 4 asthmatic donors.

  Dataset EGAD00001009687